Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

A distributed, collaborative intelligent agent system approach for proactive postmarketing drug safety surveillance.

Ji Y, Ying H, Farber MS, Yen J, Dews P, Miller RE, Massanari RM.

IEEE Trans Inf Technol Biomed. 2010 May;14(3):826-37. doi: 10.1109/TITB.2009.2037007.

2.

Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride.

Shaffer D, Butterfield M, Pamer C, Mackey AC.

J Am Pharm Assoc (2003). 2004 Nov-Dec;44(6):661-5.

PMID:
15637848
3.

Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone.

Wilkinson JJ, Force RW, Cady PS.

Pharmacotherapy. 2004 Aug;24(8):978-86.

PMID:
15338846
4.
5.

Cholinergic neurotransmission participates in increased food intake induced by NMDA receptor blockade.

Covasa M, Ritter RC, Burns GA.

Am J Physiol Regul Integr Comp Physiol. 2003 Sep;285(3):R641-8.

6.

The youngest children are too frequently subject to drug errors, study says.

Levenson D.

Rep Med Guidel Outcomes Res. 2002 Nov 29;13(23):5-7. No abstract available.

PMID:
12731479
7.

The impact of wording in "Dear doctor" letters and in black box labels.

Weatherby LB, Nordstrom BL, Fife D, Walker AM.

Clin Pharmacol Ther. 2002 Dec;72(6):735-42.

PMID:
12496755
8.

Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown.

Alfaro CL.

Psychopharmacol Bull. 2001 Autumn;35(4):80-93. Review.

PMID:
12397858
9.

Changes in related drug class utilization after market withdrawal of cisapride.

Glessner MR, Heller DA.

Am J Manag Care. 2002 Mar;8(3):243-50.

10.

Cisapride--a word of caution.

Rana S, Sharma B.

J Assoc Physicians India. 2001 Apr;49:495. No abstract available.

PMID:
11762637
11.

Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.

Wysowski DK, Corken A, Gallo-Torres H, Talarico L, Rodriguez EM.

Am J Gastroenterol. 2001 Jun;96(6):1698-703.

PMID:
11419817
12.

Cisapride and patient information leaflets.

Sukkari SR, Sasich LD.

CMAJ. 2001 May 1;164(9):1276-8; author reply 1278-9. No abstract available.

13.

Lessons from cisapride.

[No authors listed]

CMAJ. 2001 May 1;164(9):1269, 1271. English, French. No abstract available.

14.

Contraindicated use of cisapride: impact of food and drug administration regulatory action.

Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, Chan KA, Platt R, Schech SD, Ray WA.

JAMA. 2000 Dec 20;284(23):3036-9.

PMID:
11122591
16.

Update from the Canadian Dyspepsia Working Group.

Veldhuyzen van Zanten SJ, Flook N, Chiba N, Armstrong D, Barkun A, Bradette M, Thomson A, Bursey F, Blackshaw P, Frail D, Sinclair P.

CMAJ. 2000 Sep 19;163(6):696. No abstract available.

17.

NASPGN and ESPGHAN on the use of cisapride.

Spielberg SP.

J Pediatr Gastroenterol Nutr. 2000 Aug;31(2):212-3. No abstract available.

PMID:
10941984
18.

The FDA: protector or puppet?

Terpening CM.

Pharmacotherapy. 2000 Jul;20(7):860-1. No abstract available.

PMID:
10907979
19.

Drug recalls underscore safety concerns.

Greene HL.

Health News. 2000 May;6(5):4. No abstract available.

PMID:
10851966
20.

Cisapride to be taken off market, placed in controlled-access plan.

[No authors listed]

Am J Health Syst Pharm. 2000 May 1;57(9):834. No abstract available.

PMID:
10840517
Items per page

Supplemental Content

Loading ...
Support Center